WARNING-

Cardiomyopathy- Transtumab can result in subclinical and clinical cardiac failure manifesting as cardiac failure CHF anadecreased left ventrucular ejection fraction

Evaluate le ft ventricular fuction in all patients prior to and during treatment with trantuzumab

Infusion reaction and pulmonary toxicity-                                                                                Transtuzumab admin can result in serious infusion reaction and  pulmonary toxicity. Fatal infusion reaction have been reported

Pharmacology-                                                                                                          Transtuzumab is a humanized immuglobullin  GI kapps monoclonal  antibody that electively binds with high affinity to the extracelular   domain of the HER2 protein                                 

Absorption and Distrubution-                                                                                               The pharmocokientics of transzumab were studied  in women with metastic cancer. Short duration of IV infusion of transtuzumab 10 to 500mg once weekly demonstrated  dose dependent pharmacokinetcis.

Mean halif life increase and clearance decreased with increasing dose level